Letrozol SUN 2,5 mg

Description

Indications

Adjuvant therapy of early stage hormone-dependent breast cancer in postmenopausal women. Continuation of adjuvant treatment of early stage hormone-dependent breast cancer in postmenopausal women who have previously received standard adjuvant treatment with tamoxifen for 5 years.First-line treatment of late stage hormone-dependent breast cancer in postmenopausal women. Late stage breast cancer in women with natural or artificially induced menopause, after recurrence or progression of disease, who have previously been treated with anti-estrogens.

Method of administration

Adult and elderly patients The recommended dose is 2.5 mg once daily. No dose adjustment is required in elderly patients. If adjuvant therapy is indicated, treatment is recommended for 5 years or until tumour recurrence. When adjuvant therapy is indicated, there is a 2-year clinical experience (mean duration of treatment 25 months).When adjuvant therapy is indicated, there is a 4-year clinical experience (mean duration of treatment).In patients with end-stage disease or metastatic tumour, treatment with letrozole should be continued as long as tumour progression occurs. Children Not applicable. Patients with renal and/or hepatic impairmentDose adjustment in patients with renal impairment with creatinine clearance greater than 30 ml/min is not required. There are insufficient data in patients with renal impairment with creatinine clearance below 30 ml/min or patients with severe hepatic impairment.